v3.26.3
Revenue
9 Months Ended
Sep. 30, 2026
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The Company earns substantially all of its revenue from investment advisory, medical device operations (including software licensing, fee-per-test, and hardware sales), and other investment management services. The table below summarizes the Company's investment advisory fees, medical device revenues, and other revenue (in thousands):
SuccessorPredecessor
Three Months Ended
September 30, 2026
Period From September 12, 2025 to September 30, 2025Period From July 1, 2025 to September 11, 2025
Investment advisory fees$1,559 $246 $1,283 
Medical device revenues1,133 — — 
Other revenue4 9 5 
Total revenue$2,696 $255 $1,288 
SuccessorPredecessor
Nine Months Ended
September 30, 2026
Period From September 12, 2025 to September 30, 2025Period From January 1, 2025 to September 11, 2025
Investment advisory fees$4,418 $246 $4,187 
Medical device revenues3,891 — — 
Other revenue88 9 35 
Total revenue$8,397 $255 $4,222 
No individual customer accounted for 10% or greater of revenue for any period.